Showing results (101-110 of 245) with videos related to
Sort By:
Pageof 25
Anticancer Research|August 28, 2004
Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancerFabio Puglisi, Mauro Mansutti, Giuseppe Aprile, et al.Cancer Chemotherapy and Pharmacology|July 25, 2014
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapyDorothy M Keefe, Linda S Elting, Hoang T Nguyen, et al.Recenti Progressi in Medicina|August 28, 2025
Quality of life among retired oncologists and their willingness to serve: a nationwide representative surveySandro Barni, Luigi Cavanna, Paolo Tralongo, et al.The Oncologist|February 27, 2023
Implementation of Precision Oncology in Clinical Practice: Results of a National Survey for Health Care ProfessionalsGianpiero Fasola, Maria C Barducci, Giacomo Pelizzari, et al.Oncotarget|August 27, 2015
Timing and extent of response in colorectal cancer: critical review of current data and implication for future trialsGiuseppe Aprile, Caterina Fontanella, Marta Bonotto, et al.Plos One|July 26, 2014
Excitability of the motor cortex in de novo patients with celiac diseaseGiovanni Pennisi, Giuseppe Lanza, Salvatore Giuffrida, et al.Oncotarget|September 4, 2015
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical managementMichela Del Prete, Riccardo Giampieri, Fotios Loupakis, et al.Critical Reviews in Oncology/Hematology|February 25, 2016
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?Riccardo Giampieri, Marta Caporale, Filippo Pietrantonio, et al.BMC Cancer|October 20, 2023
Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysisHuilin Xu, Dedong Cao, Dingjie Zhou, et al.Journal of Geriatric Oncology|October 30, 2021
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT studyGerardo Rosati, Domenico Corsi, Antonio Avallone, et al.Pageof 25